Lichen Planus
Conditions
Interventions
Experimental group:Oral JAK inhibitors
Sponsors
Dematology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Outpatient patients aged 18-60, regardless of gender; 2. Clinically diagnosed with nail lichen planus (requiring typical clinical manifestations such as nail plate thickening, longitudinal ridging, splitting, and atrophy, confirmed by dermatoscopy or nail biopsy pathology); 3. Involving =2 nails, with ineffective treatment or recurrence after first-line therapy (such as topical potent glucocorticoids, intralesional injection, cryotherapy, or laser therapy), and a target nail damage severity score (e.g., tNLPSI score) of =3 points for at least one target nail; 4. Patients voluntarily participate and sign an informed consent form, commit to compliance with the study protocol, and attend follow-up visits on time; 5. Subjects agree to use effective contraception from the date of signing the ICF until 6 months after the last administration of the study drug. 7.Women of childbearing potential must have a negative pregnancy test result within 7 days before the first dose of the study drug.
Exclusion criteria
Exclusion criteria: 1. Received systemic immunosuppressants (such as methotrexate, cyclosporine, etc.) treatment within the past month; 2. Patients who have previously used JAK inhibitors or are allergic to JAK inhibitors or their excipients; 3. Patients with severe underlying diseases (such as active infection, malignant tumor, severe cardiovascular disease, abnormal liver function (ALT/AST > 2 times ULN), renal insufficiency (eGFR < 60 mL/min/1.73m²)); 4. Received live vaccines within the past month or plan to receive live vaccines during the study period; 5. History of deep vein thrombosis (DVT) or pulmonary embolism (PE), or presence of high thrombosis risk (such as prolonged bed rest, hereditary thrombophilia); 6. Patients with other concurrent conditions that may interfere with efficacy evaluation (such as nail psoriasis, onychomycosis); 7.The subject is deemed unsuitable for inclusion by the investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Typical Type A Lichen Planus Severity Index Score ; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS score;Peak Itch Numerical Rating;Dermatology Life Quality Index (DLQI) score; | — |
Countries
China
Contacts
Public ContactZhang lian
Dematology Hospital of Southern Medical University
Outcome results
None listed